Page 4 - Agvhd News Today

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD review how chronic GvHD is diagnosed, the different types of chronic GvHD, and key risk factors for the disease.

Expert clinicians discuss first-line treatment methodologies for chronic GvHD, with a focus on tailoring treatments to the patient.

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

A young man has revealed the symptoms that led to his devastating diagnosis blood cancer diagnosis.

Patent will allow the development of an industrial biomarker analysis kit which could be available worldwide - News - PharmaTimes

Pashna Munshi, MD, discusses how acute GVHD is staged and graded, and the common frontline treatment options.

Pashna Munshi, MD, reviews the differences between acute and chronic GVHD.

A low volatility income ETF like LVHD could be poised to ride out a possible recession this year, with earnings season a key indicator.

Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.

Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.